Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|September 17, 2025
Characterization of Next-Generation Inhibitors for the Inward-Rectifier Potassium Channel Kir2.1: Discovery of VU6080824Renn A Duncan, Daniel H Haymer, Roman M Lazarenko, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2017
Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonistsAaron M Bender, Rebecca L Weiner, Vincent B Luscombe, et al.
Molecular Pharmacology|June 14, 2018
Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992Sujay V Kharade, Haruto Kurata, Aaron M Bender, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M1 Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
Journal of Medicinal Chemistry|February 5, 2026
Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2Daniel H Haymer, Renn A Duncan, Alice L Rodriguez, et al.
JACC. Basic to Translational Science|December 14, 2023
Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment of Pulmonary Arterial HypertensionMichael S Valentine, Aaron M Bender, Sheila Shay, et al.
Cancer Research|October 22, 2009
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethalityLara S Collier, David J Adams, Christopher S Hackett, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
ACS Chemical Neuroscience|August 28, 2024
Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup CandidateJulie L Engers, Katrina A Bollinger, Rory A Capstick, et al.
Pageof 5